Arovella Therapeutics Ltd
ALA
Company Profile
Business description
Arovella Therapeutics Ltd is a biotechnology company focused on developing its invariant natural killer T (iNKT) cell therapy platform from Imperial College London to treat blood cancers and solid tumours. The company's lead iNKT cell product is ALA-101. ALA-101 consists of iNKT cells engineered to produce a Chimeric Antigen Receptor (CAR) targeting CD19 on their surface. This CD19-targeting CAR allows the iNKT cells to find and kill tumour cells that express CD19.
Contact
84 Hotham Street
Corporate One
PrestonVIC3072
AUST: +61 398636472
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
30 June 2026
Employees
44
Stocks News & Analysis
stocks
Picking dividend shares in 2026? Here’s where to look
A new report from Morningstar shows opportunities for income investors.
stocks
Ahead of earnings, is Nvidia a buy, a sell, or fairly valued?
With outstanding long-term estimates, here’s what we think of Nvidia stock.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,808.80 | 47.80 | -0.54% |
| CAC 40 | 8,126.33 | 43.76 | -0.54% |
| DAX 40 | 23,588.99 | 287.56 | -1.20% |
| Dow JONES (US) | 47,055.31 | 401.91 | -0.85% |
| FTSE 100 | 9,687.94 | 10.43 | -0.11% |
| HKSE | 26,172.27 | 400.19 | -1.51% |
| NASDAQ | 22,883.94 | 16.65 | -0.07% |
| Nikkei 225 | 49,318.96 | 1,057.57 | -2.10% |
| NZX 50 Index | 13,436.11 | 28.35 | -0.21% |
| S&P 500 | 6,723.72 | 10.39 | -0.15% |
| S&P/ASX 200 | 8,536.40 | 42.40 | -0.49% |
| SSE Composite Index | 3,971.84 | 0.19 | -0.00% |